A Perspective From Industry – A Conversation With Richard S. Geary, Ph.D. Executive Vice President, Chief Development Officer at Ionis Pharmaceuticals
Speaker: Richard S. Geary, Ph.D. Date: February 10, 2022 Time: 11-12 EST Description: The OTS Webinar series is pleased ...
A Conversation with OTS President, Prof. David Corey
Speaker: David Corey, Ph.D. Date: January 13, 2022 Time: 11-12 EST Description: Join us for an open discussion on ...
Development of N=1 RNA Therapies in the Netherlands and Europe
After the development of Milasen in the United States, there has been an increase in the development of antisense oligonucleotide therapies for patients with unique mutations.
